Colby Cosh: There's no point to gatekeeping MAiD if doctors never say 'no'
On Sunday the New York Times Magazine published a feature about Canada's legal regime for assisted suicide, wrapping large volumes of reporting on law, ethics and medicine around the individual story of Paula Ritchie, an Ontario woman who sought and received 'MAiD' after an unhappy life full of pain and misery.
Article content
Katie Engelhart's story plays pretty fair with an explosive social issue that is of increasing global concern. She knows the NYT 's world audience is aware of Canada's avant-garde experiment with the facilitation of medical suicide for patients who don't have terminal illnesses, and she doesn't stack the deck either way.
Article content
Article content
She's not under any fanciful illusions about the quality of Canadian medicine or Canadian welfare, specifically describing how mere administrative mistakes can lead to intolerable suffering for which the Canadian state now provides a fatal exit. She acknowledges that there was nothing demonstrably wrong with Ritchie apart from mental illness and ill-specified 'functional disorders'; there is some accounting of times she refused potentially helpful treatments out of sheer despair.
Article content
Article content
At the end of the story, as Ritchie is put to death like a sick pet with friends and family around her, one can't help thinking she might be better off — and one can't help wondering whether we are playing with fire. That very uncertainty is the whole problem with MAiD, of course. Because it is an experiment, we're left trying to extrapolate the second-order social effects of a legal regime over which nobody has complete political control. (MAiD is, to say the least, not the only social problem of this nature.)
Article content
Canadian law doesn't yet theoretically allow for MAiD for mental illness alone without some accompanying physical diagnosis. But a diagnosis is a label, and there is a myriad of labels available for those 'functional disorders' and chronic-pain syndromes whether or not there is any observable biological signature. If you want desperately to die with a doctor's help, as Ritchie did, you can probably find one who has an extreme ideological commitment to total patient autonomy, as Ritchie did, and get him to sign off, as Ritchie did.
Article content
Article content
I don't know of any case where a doctor gave MAiD to anybody who didn't have a clear, emphatically expressed desire to die. And, as Engelhart points out, there is not yet any apparent epidemic of 'Track 2' assisted suicides not involving terminal or irresolvable physical illness. But her story hints uneasily that Canada may simply be turning euthanasia into just another medical specialty, or indeed turning some doctors into vending machines for lethal poisons. They're being asked, in Track 2 cases, to approve and facilitate suicide, or to refuse to do so, after assessing a patient's purely subjective suffering. One uneasy physician interviewee asks: 'If you want to allow people to end their lives when they want to, then put suicide kits in hardware stores, right?'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
43 minutes ago
- CTV News
Construction begins on Saskatoon's newest supportive housing unit
A prayer and groundbreaking ceremony has been held on the future site of Saskatoon's newest supportive housing unit. The 16 unit, 24 bedroom building will provide a safe space for those removing themselves from abusive situations. The facility is thanks to the Metis Nation of Saskatchewan, alongside partners from all three levels of government. 'We need to remember that our people, our citizens, are distinct and they're unique, and we cannot expect the colonial systems to continue to implement programs and services that are not for them,' said Beverly Fullerton, Minister of Health, Mental Health & Addictions for Metis Nation Saskatchewan. 'With Metis Nation, it's absolutely amazing that we can actually address the issues and then wrap our citizens around that love and care and respect they deserve.' The facility will provide culturally-appropriate services, including childcare, education and round-the-clock support workers. While the space has been curated by Saskatchewan's Metis Nation, the building is open to Metis, Indigenous and non-Indigenous women and children, and members of the 2SLGBTQIA+ community. 'There are no borders. There shouldn't be any borders,' said Glen McCallum, President of Metis Nation Saskatchewan. 'That's why this place is going to be open for Metis, First Nations, Inuit and non-Indigenous folks that are struggling with domestic violence, and to be able to have a safe place to come to.' The location for the building has a special place in the hearts of those on the organizing team. Located in one of Saskatoon's newer neighbourhoods, Kensington, Fullerton says the location will help remove some of the stigma that comes along with supportive housing. 'When we think about our society, we'll normally look at whether it's homeless, domestic violence victims or addictions. There's some weird reason why we assume they need to be in the not-so-great areas of our cities, and so they offer them a space and show they're worthy and they are welcome.' The facility is expected to be operating by fall of 2026. 'We still have a lot of work to do behind the scenes, making sure our programs and supports are going to be addressing the issues,' added Fullerton. 'Things like this, we don't always want to rush them, but we know the need is there. So we'll be doing everything we can to get it open as soon as we can.'
National Post
43 minutes ago
- National Post
Health Canada approves Ozempic for kidney protection in Type 2 diabetics
Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues — the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
National Post
43 minutes ago
- National Post
Hyperice Unveils Next Generation of Contrast Therapy Innovation, Hyperice X 2 Knee and Hyperice X 2 Shoulder
Driven by Athlete Feedback, the New Hyperice X 2 Unlocks a New Era of Contrast Recovery Tech With Powerful Multi-Level Compression Article content IRVINE, Calif. — Hyperice, a global high-performance wellness brand, today announced the global launch of Hyperice X 2, the next generation of its best-selling Hyperice X contrast therapy line. Born from the acquisition of RecoverX in 2021 and refined through athlete testing, Hyperice X 2 is the most advanced portable contrast therapy device on the market. The Hyperice X 2 Knee and Hyperice X 2 Shoulder feature major upgrades from their predecessor devices, including deeper cold, stronger heat, and a built-in compression system to aid athletes and active users with more effective warm-up and recovery strategies. Article content Article content 'With Hyperice X 2 Shoulder and Hyperice X 2 Knee, we're not just advancing recovery, we're redefining it.' Article content Hyperice X 2 marks the most substantial evolution in technology from its first-generation product. The breakthrough innovation was built and refined through a rigorous feedback loop with elite athletes. Every detail, from contrast and compression ranges to fit and portability, has been accounted for, ensuring the product meets the demands of elite athletes on the sideline alongside everyday individuals. Article content 'Recovery and wellness are fundamental to living well, from professional athletes to people of all ages,' said Jim Huether, CEO of Hyperice. 'Our mission is to provide the most advanced and effective solutions to help people move, feel, and perform better every day. With Hyperice X 2 Shoulder and Hyperice X 2 Knee, we're not just advancing recovery, we're redefining it. This next generation maintains the mobility and power of its predecessor while seamlessly fusing contrast therapy and compression into a sleek, more practical design.' Article content With advanced technology tested and proven by athletes, Hyperice X 2 Knee and Hyperice X 2 Shoulder bring elite-level warm-up and recovery contrast therapy solutions in a new, user-friendly device designed for everyday use. Whether training, rehabbing from injury or surgery, or staying active on the go, users can prime their bodies, recover faster, and perform at their best. Article content Key Features: Article content Addition of compression: Five levels of compression (up to 160mmHg) push temperatures deeper into the tissue, allowing users to tailor the compression to their needs and achieve a more customized fit. Targeted contrast therapy: Expanded temperature ranges now span from 40°F (4°C) to 121°F (49°C), with five levels of cooling and five levels of heating, to ease inflammation and boost circulation as needed. Up from the original Hyperice X range at 45°F (7°C) to 113°F (45°C). Smart control and all-in-one mobility: A new all-in-one OLED display allows seamless switching between hot, cold, and contrast therapy, as well as select compression levels. Hyperice X 2 is cord-free for use on the move, with an option to plug in to the wall for extended rehab sessions. Manual and Bluetooth compatibility: New to Hyperice X 2, users can use the device with or without Bluetooth connectivity to the Hyperice app, allowing pros to leverage the technology on the sidelines easier than ever before. Extended battery life: Up to 1.5 hours of continuous portable use (1 hour on max cold, 1 hour on max contrast, and 1.5 hours on max heat) – 34% more capacity compared to the original Hyperice X line. Lightweight and portable: Just 2.5 lbs and TSA-friendly, Hyperice X 2 Knee and Hyperice X 2 Shoulder prioritize portability and ease of use. Each device is designed to fit both the right and left sides, to allow for increased versatility and on-the-go therapy. Article content From Generation 1 to Game-Changer Article content Building on the success of the original Hyperice X Knee and Hyperice X Shoulder models, Hyperice X 2 uses thermoelectric systems to deliver instant heat and cold temperatures on demand, without the need for ice or liquid. Hyperice X 2 introduces a clinically inspired multi-level compression system that drives temperatures deeper into tissue, ultra-convenient on-device smart controls, and cord-free portability. Now, this athlete-endorsed technology comes in a lightweight, portable device designed to help anyone, anytime, anywhere. Article content 'I've put everything into this off-season to come back stronger, and recovery is where that work pays off with the Hyperice X 2 Shoulder playing a major role in my routine,' said Jayden Daniels, Washington Commanders quarterback and Hyperice athlete. 'I can push my limits on the field because the built-in compression elevates my warm-up, and the contrast therapy helps me bounce back quickly for peak performance.' Article content Benefits of contrast therapy include: Article content Reduces swelling and pain: Contrast moves fluid, while compression limits buildup to ease inflammation and discomfort. Relaxes muscles and boosts circulation: Heat loosens tight muscles, cold calms spasms, and both, paired with compression, improve blood flow. Improves range of motion: Reduces stiffness, mobilizes joints, and softens tissue for smoother, safer movement. Flushes waste: Contrast and compression work together to speed up the removal of lactic acid and other byproducts. Aids warm-up and recovery: Increases tissue readiness before activity and helps muscles reset and recover after. Article content The Hyperice X 2 Knee and Hyperice X 2 Shoulder are available now in the U.S. at Best Buy, Dick's Sporting Goods, and REI for $449. In Europe and the UK, the same cutting-edge technology will be available at as Hyperice Contrast 2 on September 15, retailing for £399 or €449. Article content Assets can be found Article content . Article content About Hyperice Article content Article content Article content Article content Article content Contacts
